11 research outputs found

    hTERT mRNA diagnostic accuracy. Comparison with serum PSA.

    No full text
    <p>ROC curves show that plasma hTERT mRNA, but not serum PSA, discriminates between PCa patients and healthy individuals or patients with prostatitis or BPH. Plasma hTERT mRNA shows higher sensitivity (85% vs 83%), specificity (90% vs 47%), PPV (83% vs 56%), NPV (92% vs 77%) and AUC ROC (0.932 vs 0.651) than PSA with respect to PCa diagnosis. Pairwise comparison of hTERT mRNA and PSA ROC curves showed significant differences (p<0.001).</p

    Results of the logistic regression analysis predicting PCa diagnosis.

    No full text
    <p>DRE: Digital Rectal Examination; TRUS: Transrectal Ultrasonography; CI: Confidence Intervals;</p>*<p>Logistic regression analysis, p–values less than 0.05 were considered statistically significant.</p

    Flow diagram showing that PSA screening results in a high percentage of unnecessary biopsies.

    No full text
    <p>One hundred and five consecutive patients with elevated PSA levels underwent prostate biopsy. Forty-six of the 105 patients (44%) were diagnosed with PCa, and fifty-nine patients (56%) showed no evidence of cancer. PCa: Prostate Cancer BPH: Benign Prostatic Hyperplasia.</p

    Kaplan-Meier analysis of time to biochemical recurrence.

    No full text
    <p>Kaplan-Meier curves indicate that there are significant differences in recurrence-free survival between high and low hTERT groups (A) but not between high and low serum PSA groups (B).</p
    corecore